New England Research & Management Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 11.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 39,118 shares of the company’s stock after buying an additional 4,000 shares during the quarter. Johnson & Johnson makes up 3.1% of New England Research & Management Inc.’s holdings, making the stock its 2nd biggest position. New England Research & Management Inc.’s holdings in Johnson & Johnson were worth $4,747,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Stelac Advisory Services LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at $108,000. Financial Gravity Wealth Inc. purchased a new position in Johnson & Johnson during the first quarter valued at $105,000. Princeton Capital Management LLC purchased a new position in Johnson & Johnson during the first quarter valued at $141,000. Smart Portfolios LLC purchased a new position in Johnson & Johnson during the first quarter valued at $150,000. Finally, Fenimore Asset Management Inc. purchased a new position in shares of Johnson & Johnson in the fourth quarter worth about $217,000. Institutional investors own 66.80% of the company’s stock.
Shares of JNJ stock opened at $139.49 on Monday. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.32. The stock has a market cap of $373.89 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 2.13 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 17th. The company reported $2.10 EPS for the quarter, topping analysts’ consensus estimates of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The company had revenue of $20.83 billion for the quarter, compared to the consensus estimate of $20.39 billion. During the same period in the previous year, the firm earned $1.83 earnings per share. Johnson & Johnson’s quarterly revenue was up 10.6% compared to the same quarter last year. research analysts anticipate that Johnson & Johnson will post 8.14 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 11th. Shareholders of record on Tuesday, August 28th were paid a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date was Monday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the transaction, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is owned by insiders.
Several equities analysts have recently weighed in on the stock. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Sanford C. Bernstein assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price target on the stock. Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, July 15th. Credit Suisse Group set a $151.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, June 12th. Finally, Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $142.87.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Do You Need a Fiduciary?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.